Is fosfomycin appropriate for treating a methicillin‑resistant coagulase‑negative Staphylococcus (MRCoNS) infection that is susceptible to fosfomycin, and what dosing regimen should be used?

Fosfomycin for MRCoNS Infections

Fosfomycin is NOT recommended as monotherapy for methicillin-resistant coagulase-negative Staphylococcus (MRCoNS) infections, despite in vitro susceptibility, due to rapid emergence of resistance and lack of established clinical efficacy data for this specific pathogen.

Key Clinical Considerations

Why Fosfomycin Alone is Inadequate

• Rapid resistance development: Mutants resistant to fosfomycin emerge readily during monotherapy, even when initial susceptibility is demonstrated 1
• FDA-approved indication: Fosfomycin is only approved for uncomplicated urinary tract infections caused by E. coli and Enterococcus faecalis 2
• No guideline support: IDSA guidelines for MRSA/resistant staphylococci do not include fosfomycin as a recommended agent for systemic MRCoNS infections 3, 4

When Fosfomycin May Have a Role

If you must use fosfomycin for MRCoNS, it should ONLY be used in combination therapy, never as monotherapy:

• Combination requirement: Fosfomycin must be paired with rifampin, ciprofloxacin, or other agents to prevent resistance emergence 1
• Synergy demonstrated: In vitro studies show MIC synergy when fosfomycin is combined with rifampin or ciprofloxacin against CoNS 1, 5
• Limited clinical data: Recent evidence suggests adjunctive fosfomycin may improve bacterial clearance in S. aureus bacteremia but increases toxicity risk 6

Recommended Treatment Approach for MRCoNS

First-Line Therapy (Based on IDSA Guidelines)

For oxacillin-resistant CoNS infections 3, 4:

Acute treatment (4-6 weeks):

• Vancomycin 15-20 mg/kg IV every 8-12 hours (target trough 10-15 mcg/mL for CoNS)
• Alternative: Daptomycin 6 mg/kg IV daily
• Alternative: Linezolid 600 mg PO/IV twice daily

Chronic suppression (if needed):

• Trimethoprim-sulfamethoxazole 1-2 DS tablets PO twice daily 3
• Alternative: Minocycline or doxycycline 100 mg PO twice daily

Critical Pitfalls to Avoid

1. Do not use fosfomycin monotherapy - resistance emerges within days
2. Do not assume oral fosfomycin achieves adequate systemic levels - it is designed for urinary tract concentrations only 2
3. Do not extrapolate S. aureus data to CoNS - these are distinct pathogens with different resistance mechanisms 7, 8

Special Circumstances

Prosthetic Joint Infection with MRCoNS

If dealing with prosthetic joint infection 3:

• Vancomycin 15 mg/kg IV every 12 hours PLUS
• Rifampin 300-450 mg PO twice daily (after initial 2 weeks of IV therapy)
• Duration: 2-6 weeks IV, then transition to oral rifampin + companion drug for total 3 months

If Standard Agents Fail

Consider infectious disease consultation for:

• High-dose daptomycin (8-10 mg/kg/day) + fosfomycin combination (based on limited S. aureus data 9)
• Intravenous fosfomycin 4-6 g every 6 hours (not the oral formulation) in combination therapy
• This is off-label and should only be attempted with specialist guidance

Bottom Line

The presence of in vitro fosfomycin susceptibility does NOT justify its use as monotherapy for MRCoNS. Standard guideline-recommended agents (vancomycin, daptomycin, or linezolid) remain the appropriate first-line choices 3, 4. Fosfomycin may only be considered as adjunctive therapy in refractory cases under specialist supervision, never alone.